Companies / SER
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Ticker SER Exchange NYSE Sector Healthcare Industry Biotechnology Market cap $36.44M 52-week range $1.14 - $4.26
Valuation Share price $1.35 (close of Nov 18, 2026) P/E (TTM) -0.79x Price to book 2.62x Price to free cash flow -1.60x Enterprise value $20.41M Book value per share $0.53
Price performance Period Change 1 day -1.46% 5 days -10.00% 1 month -21.51% 3 months -48.47% 6 months -10.60% Year to date -29.32% 1 year -64.10% 3 years -91.22% 5 years -95.08% All time -98.60%
Short interest As of Oct 30, 2026 Short % of float 0.21% Shares short 46.79K Days to cover 0.81 Change since prior report +6.65% Source FINRA consolidated short interest
Profitability and growth Return on assets -275.96% Net margin -14,755.38% EBITDA margin -18,401.54% Revenue growth 132.14%
Cash flow and balance sheet Free cash flow yield (TTM) -62.66% Current ratio 4.62x Net debt to EBITDA 0.68x
Latest reported year Period end Dec 31, 2025 Fiscal year 2025 Revenue $130.00K EBITDA -$23.92M Net income -$19.18M Research and development $13.15M Interest expense $213.00K
Income statement by year Period end Revenue Gross profit Net income 2025-12-31 $130.00K - -$19.18M 2024-12-31 $56.00K - -$11.14M 2023-12-31 - - $5.27M 2022-12-31 $34.00K $21.00K -$10.46M 2021-12-31 $144.00K $125.00K -$8.68M 2020-12-31 $361.00K $335.00K -$10.87M 2019-12-31 $1.73M $1.48M -$12.15M 2018-12-31 $1.40M $1.03M -$7.50M 2017-12-31 $1.40M $1.24M -$6.58M 2016-12-31 $1.67M - -$15.49M
Margins and returns by year Period end Gross margin Net margin Return on equity Return on capital 2025-12-31 - -14,755.38% - - 2024-12-31 - -19,894.64% - - 2022-12-31 61.76% -30,770.59% - - 2021-12-31 86.81% -6,024.31% - - 2020-12-31 92.80% -3,009.70% - - 2019-12-31 85.88% -703.36% - - 2018-12-31 73.93% -537.39% -91.14% -136.62% 2017-12-31 88.03% -468.66% -79.10% -80.09% 2016-12-31 - -929.89% - -
Cash and debt by year Period end Cash Debt 2025-12-31 $3.06M $2.95M 2024-12-31 $3.67M - 2023-12-31 $7.62M $2.98M 2022-12-31 $645.00K $18.12M 2021-12-31 $584.00K $13.20M 2020-12-31 $527.00K - 2019-12-31 $2.35M - 2018-12-31 $6.71M - 2017-12-31 $7.38M - 2016-12-31 $259.00K -
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 -$18.01M $3.79M 2024-12-31 -$17.16M $2.60M 2023-12-31 -$2.98M $25.00K 2022-12-31 -$5.94M $760.00K 2021-12-31 -$7.86M $999.00K 2020-12-31 -$7.84M $909.00K 2019-12-31 -$10.80M $1.91M 2018-12-31 -$8.02M $1.28M 2017-12-31 -$6.29M $114.00K 2016-12-31 -$8.45M -
Investor relations Next earnings report Next confirmed report Nov 19, 2026 Past earnings dates Reported Fiscal period EPS estimate 2026-11-12 Sep 2026 - 2026-08-13 Jun 2026 - 2026-05-14 Mar 2026 - 2026-03-25 Dec 2025 - 2025-11-13 Sep 2025 -$0.47 2025-08-11 Jun 2025 -$0.36 2025-05-08 Mar 2025 - 2025-03-24 Dec 2024 -
Filings and sources Company website serinatx.com SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports
Similar companies Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades